Citations (73)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Michael D Levitt & David G Levitt. (2019) Use Of Quantitative Modelling To Elucidate The Roles Of The Liver, Gut, Kidney, And Muscle In Ammonia Homeostasis And How Lactulose And Rifaximin Alter This Homeostasis. International Journal of General Medicine 12, pages 367-380.
Read now
Read now
Christopher Chang. (2018) Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin. Clinical and Experimental Gastroenterology 11, pages 335-345.
Read now
Read now
David G Levitt & Michael D Levitt. (2018) A model of blood-ammonia homeostasis based on a quantitative analysis of nitrogen metabolism in the multiple organs involved in the production, catabolism, and excretion of ammonia in humans. Clinical and Experimental Gastroenterology 11, pages 193-215.
Read now
Read now
Nina Kimer, Aleksander Krag & Lise L Gluud. (2014) Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Preference and Adherence 8, pages 331-338.
Read now
Read now
Kristina R. Chacko & Samuel H. Sigal. (2013) Update on Management of Patients With Overt Hepatic Encephalopathy. Hospital Practice 41:3, pages 48-59.
Read now
Read now
Maddalena Diana Iadevaia, Anna Del Prete, Claudia Cesaro, Laura Gaeta, Claudio Zulli & Carmelina Loguercio. (2011) Rifaximin in the treatment of hepatic encephalopathy. Hepatic Medicine: Evidence and Research 3, pages 109-117.
Read now
Read now
Kevin Mullen & Ravi Prakash. (2010) Rifaximin for the treatment of hepatic encephalopathy. Expert Review of Gastroenterology & Hepatology 4:6, pages 665-677.
Read now
Read now
Jessica Cottreau, Shannon F Baker, Herbert L DuPont & Kevin W Garey. (2010) Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Review of Anti-infective Therapy 8:7, pages 747-760.
Read now
Read now
Laura Gerard, Kevin W Garey & Herbert L DuPont. (2005) Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Review of Anti-infective Therapy 3:2, pages 201-211.
Read now
Read now
Articles from other publishers (64)
Harry D Zacharias, Fady Kamel, Jaclyn Tan, Nina Kimer, Lise Lotte Gluud & Marsha Y Morgan. (2023) Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database of Systematic Reviews 2023:7.
Crossref
Crossref
Alexandros O. Konstantinidis, Katerina K. Adamama-Moraitou, Michail N. Patsikas & Lysimachos G. Papazoglou. (2023) Congenital Portosystemic Shunts in Dogs and Cats: Treatment, Complications and Prognosis. Veterinary Sciences 10:5, pages 346.
Crossref
Crossref
Paulina Vidal-Cevallos, Norberto C. Chávez-Tapia & Misael Uribe. (2022) Current approaches to hepatic encephalopathy. Annals of Hepatology 27:6, pages 100757.
Crossref
Crossref
Xianghui Han, Zhanyang Luo, Wenyi Wang, Peiyong Zheng, Tian Li, Zubing Mei & Jianyi Wang. (2021) Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy. Frontiers in Pharmacology 12.
Crossref
Crossref
Christopher F. Rose, Piero Amodio, Jasmohan S. Bajaj, Radha Krishan Dhiman, Sara Montagnese, Simon D. Taylor-Robinson, Hendrik Vilstrup & Rajiv Jalan. (2020) Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. Journal of Hepatology 73:6, pages 1526-1547.
Crossref
Crossref
Oluyemi Komolafe, Danielle Roberts, Suzanne C Freeman, Peter Wilson, Alex J Sutton, Nicola J Cooper, Chavdar S Pavlov, Elisabeth Jane Milne, Neil Hawkins, Maxine Cowlin, Douglas Thorburn, Brian R Davidson, Emmanuel Tsochatzis & Kurinchi Selvan Gurusamy. (2020) Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Mark Hudson & Marcus Schuchmann. (2019) Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. European Journal of Gastroenterology & Hepatology 31:4, pages 434-450.
Crossref
Crossref
Bogdan A. Stana & Evelina Moraru. (2019) Hepatic encephalopathy - current considerations. Pediatru.ro 2:54, pages 24.
Crossref
Crossref
Maxime Mallet, Nicolas Weiss, Dominique Thabut & Marika Rudler. (2018) Why and when to measure ammonemia in cirrhosis?. Clinics and Research in Hepatology and Gastroenterology 42:6, pages 505-511.
Crossref
Crossref
Kazuyuki Suzuki, Ryujin Endo, Yasuhiro Takikawa, Fuminori Moriyasu, Yutaka Aoyagi, Hisataka Moriwaki, Shuji Terai, Isao Sakaida, Yoshiyuki Sakai, Shuhei Nishiguchi, Toru Ishikawa, Hitoshi Takagi, Atsushi Naganuma, Takuya Genda, Takafumi Ichida, Koichi Takaguchi, Katsuhiko Miyazawa & Kiwamu Okita. (2018) Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator‐blinded, active‐controlled trial and a phase III, multicenter, open trial. Hepatology Research 48:6, pages 411-423.
Crossref
Crossref
Chathur Acharya & Jasmohan S. Bajaj. 2017. Schiff's Diseases of the Liver. Schiff's Diseases of the Liver
387
410
.
Abhishek Basappanamalige Lokesh Reddy, Sabeena Kizhedath & Bindhu Vasudevan. (2017) COMPARISON OF RIFAXIMIN, LACTULOSE WITH RIFAXIMIN, LACTULOSE, BRANCHED CHAIN AMINOACIDS (BCAA) IN GRADE 1 TO GRADE 3 OF HEPATIC ENCEPHALOPATHY- NON RANDOMIZED CONTROLLED TRIAL STUDY. Journal of Evolution of Medical and Dental Sciences 6:74, pages 5314-5320.
Crossref
Crossref
K. Milewski & M. Oria. (2015) What we know: the inflammatory basis of hepatic encephalopathy. Metabolic Brain Disease 31:6, pages 1239-1247.
Crossref
Crossref
Jordi Sanchez-Delgado & Mireia Miquel. (2016) Papel de la rifaximina en el tratamiento de la encefalopatía hepática. Gastroenterología y Hepatología 39:4, pages 282-292.
Crossref
Crossref
Jordi Sanchez-Delgado & Mireia Miquel. (2016) Role of rifaximin in the treatment of hepatic encephalopathy. Gastroenterología y Hepatología (English Edition) 39:4, pages 282-292.
Crossref
Crossref
J. S. Bajaj. (2016) Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis. Alimentary Pharmacology & Therapeutics 43, pages 11-26.
Crossref
Crossref
G.-Q. Zhu, K.-Q. Shi, S. Huang, L.-R. Wang, Y.-Q. Lin, G.-Q. Huang, Y.-P. Chen, M. Braddock & M.-H. Zheng. (2015) Systematic review with network meta-analysis: the comparative effectiveness and safety of interventions in patients with overt hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 41:7, pages 624-635.
Crossref
Crossref
Shalimar & Subrat K. Acharya. (2015) Management in Acute Liver Failure. Journal of Clinical and Experimental Hepatology 5, pages S104-S115.
Crossref
Crossref
Markus Peck-Radosavljevic, Paolo Angeli, Juan Cordoba, Oliver Farges & Dominique Valla. (2015) Managing complications in cirrhotic patients. United European Gastroenterology Journal 3:1, pages 80-94.
Crossref
Crossref
P.S. Mantry, A. Mehta & R. Graydon. (2014) Efficacy and Tolerability of Rifaximin in Combination With Lactulose in End-stage Liver Disease Patients With MELD Greater Than 20: A Single Center Experience. Transplantation Proceedings 46:10, pages 3481-3486.
Crossref
Crossref
Christopher Sheasgreen, Lucy Lu & Ameen Patel. (2014) Pathophysiology, diagnosis, and management of hepatic encephalopathy. Inflammopharmacology 22:6, pages 319-326.
Crossref
Crossref
N. Kimer, A. Krag, S. Møller, F. Bendtsen & L. L. Gluud. (2014) Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 40:2, pages 123-132.
Crossref
Crossref
Juan Cordoba. (2014) Hepatic Encephalopathy: From the Pathogenesis to the New Treatments. ISRN Hepatology 2014, pages 1-16.
Crossref
Crossref
Barjesh Chander Sharma, Praveen Sharma, Manish Kumar Lunia, Siddharth Srivastava, Rohit Goyal & S K Sarin. (2013) A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. American Journal of Gastroenterology 108:9, pages 1458-1463.
Crossref
Crossref
Mateen Trimzi, Joel Trambley & Heather Patton. (2013) Hepatic Encephalopathy. Hospital Medicine Clinics 2:3, pages e386-e398.
Crossref
Crossref
Lewis W. Teperman. (2013) Impact of Pretransplant Hepatic Encephalopathy on Liver Posttransplantation Outcomes. International Journal of Hepatology 2013, pages 1-9.
Crossref
Crossref
Guy W. Neff, Michael Jones, Taylor Broda, Mark Jonas, Ravinuthala Ravi, David Novick, Tiffany E. Kaiser & Nyingi Kemmer. (2012) Durability of Rifaximin Response in Hepatic Encephalopathy. Journal of Clinical Gastroenterology 46:2, pages 168-171.
Crossref
Crossref
Seong Choon ChoeDong Ho Lee. (2012) Use of Oral Antibiotics in Elderly Gastrointestinal Patients. Journal of the Korean Geriatrics Society 16:3, pages 108.
Crossref
Crossref
Jasmohan S. Bajaj. 2012. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
267
282
.
Ravi K. Prakash & Kevin D. Mullen. 2011. Schiff's Diseases of the Liver. Schiff's Diseases of the Liver
421
444
.
&NA;. (2011) Non-absorbable disaccharides and antibacterials are the treatment of choice for hepatic encephalopathy. Drugs & Therapy Perspectives 27:6, pages 17-21.
Crossref
Crossref
Peter Ferenci & Christian Müller. 2010. Evidence‐Based Gastroenterology and Hepatology. Evidence‐Based Gastroenterology and Hepatology
636
649
.
Dennis J. Cada, Terri L. Levien & Danial E. Baker. (2010) Rifaximin. Hospital Pharmacy 45:9, pages 712-717.
Crossref
Crossref
Paula V. Phongsamran, Jiwon W. Kim, Jennifer Cupo Abbott & Angela Rosenblatt. (2010) Pharmacotherapy for Hepatic Encephalopathy. Drugs 70:9, pages 1131-1148.
Crossref
Crossref
J. Richard Thompson. (2010) Treatment Guidelines for Hepatic Encephalopathy. Pharmacotherapy 30:5, part 2, pages 4S-9S.
Crossref
Crossref
Thomas D Schiano. (2010) Treatment Options for Hepatic Encephalopathy. Pharmacotherapy 30:5, part 2, pages 16S-21S.
Crossref
Crossref
Lewis W. Teperman & Vincent P. Peyregne. (2010) Considerations on the Impact of Hepatic Encephalopathy Treatments in the Pretransplant Setting. Transplantation 89:7, pages 771-778.
Crossref
Crossref
Nathan M. Bass, Kevin D. Mullen, Arun Sanyal, Fred Poordad, Guy Neff, Carroll B. Leevy, Samuel Sigal, Muhammad Y. Sheikh, Kimberly Beavers, Todd Frederick, Lewis Teperman, Donald Hillebrand, Shirley Huang, Kunal Merchant, Audrey Shaw, Enoch Bortey & William P. Forbes. (2010) Rifaximin Treatment in Hepatic Encephalopathy. New England Journal of Medicine 362:12, pages 1071-1081.
Crossref
Crossref
DAVID P. CALFEE. 2010. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
403
417
.
Barjesh Chander Sharma, Praveen Sharma, Amit Agrawal & Shiv Kumar Sarin. (2009) Secondary Prophylaxis of Hepatic Encephalopathy: An Open-Label Randomized Controlled Trial of Lactulose Versus Placebo. Gastroenterology 137:3, pages 885-891.e1.
Crossref
Crossref
Pamela M Moye & Nancy S Yunker. (2009) Rifaximin for Hepatic Encephalopathy. Journal of Pharmacy Technology 25:2, pages 111-118.
Crossref
Crossref
Darego O Maclayton & Angie Eaton-Maxwell. (2008) Rifaximin for Treatment of Hepatic Encephalopathy. Annals of Pharmacotherapy 43:1, pages 77-84.
Crossref
Crossref
Qian Jiang, Xue-Hua Jiang, Ming-Hua Zheng, Liu-Ming Jiang, Yong-Ping Chen & Li Wang. (2008) Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. European Journal of Gastroenterology & Hepatology 20:11, pages 1064-1070.
Crossref
Crossref
Kenneth R. Lawrence & Jacqueline A. Klee. (2012) Rifaximin for the Treatment of Hepatic Encephalopathy. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:8, pages 1019-1032.
Crossref
Crossref
Rachel Tavares de Melo, Lisa Charneski & Olga Hilas. (2008) Rifaximin for the treatment of hepatic encephalopathy. American Journal of Health-System Pharmacy 65:9, pages 818-822.
Crossref
Crossref
E. HUANG, E. ESRAILIAN & B. M. R. SPIEGEL. (2007) The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis. Alimentary Pharmacology & Therapeutics 26:8, pages 1147-1161.
Crossref
Crossref
N. M. BASS. (2007) Review article: the current pharmacological therapies for hepatic encephalopathy. Alimentary Pharmacology & Therapeutics 25, pages 23-31.
Crossref
Crossref
G.W. Neff, N. Kemmer, V.C. Zacharias, T. Kaiser, C. Duncan, R. McHenry, M. Jonas, D. Novick, C. Williamson, K. Hess, M. Thomas & J. Buell. (2006) Analysis of Hospitalizations Comparing Rifaximin Versus Lactulose in the Management of Hepatic Encephalopathy. Transplantation Proceedings 38:10, pages 3552-3555.
Crossref
Crossref
J. A. Adachi & H. L. DuPont. (2006) Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders. Clinical Infectious Diseases 42:4, pages 541-547.
Crossref
Crossref
Davide Festi, Amanda Vestito, Giuseppe Mazzella, Enrico Roda & Antonio Colecchia. (2006) Management of Hepatic Encephalopathy: Focus on Antibiotic Therapy. Digestion 73:1, pages 94-101.
Crossref
Crossref
Kevin D. Mullen. 2006. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
311
331
.
David B. Huang & Herbert L. DuPont. (2005) Rifaximin—a novel antimicrobial for enteric infections. Journal of Infection 50:2, pages 97-106.
Crossref
Crossref
Yong-Han PaikKwan Sik LeeKwang-Hyub HanKun Hoon SongMyoung Hwan KimByung Soo MoonSang Hoon AhnSe Joon LeeHyo Jin ParkDong Ki LeeChae Yoon ChonSang In LeeYoung Myoung Moon. (2005) Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study. Yonsei Medical Journal 46:3, pages 399.
Crossref
Crossref
Maria Luisa Zeneroli, Rossella Avallone, Lorenzo Corsi, Ivo Venturini, Claudia Baraldi & Mario Baraldi. (2005) Management of Hepatic Encephalopathy: Role of Rifaximin. Chemotherapy 51:1, pages 90-95.
Crossref
Crossref
Peter Ferenci & Christian Müller. 2004. Evidence‐based Gastroenterology and Hepatology. Evidence‐based Gastroenterology and Hepatology
505
515
.
H.L. DuPont & Z.-D. Jiang. (2004) Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clinical Microbiology and Infection 10:11, pages 1009-1011.
Crossref
Crossref
Claudia Sama, Antonio Maria Morselli-Labate, Paolo Pianta, Laura Lambertini, Sonia Berardi & Gabriella Martini. (2004) Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study. Current Therapeutic Research 65:5, pages 413-422.
Crossref
Crossref
Rosa M Infante, Charles D Ericsson, Zhi-Dong Jiang, Shi Ke, Robert Steffen, Lise Riopel, David A Sack & Herbert L Du>Pont. (2004) Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clinical Gastroenterology and Hepatology 2:2, pages 135-138.
Crossref
Crossref
Guy de Bruyn & Edward A Graviss. (2001) A systematic review of the diagnostic accuracy of physical examination for the detection of cirrhosis. BMC Medical Informatics and Decision Making 1:1.
Crossref
Crossref
Robert Steffen. (2001) Rifaximin: A Nonabsorbed Antimicrobial as a New Tool for Treatment of Travelers'Diarrhea. Journal of Travel Medicine 8:s2, pages s34-s39.
Crossref
Crossref
Herbert L. DuPont, Zhi‐Dong Jiang, Charles D. Ericsson, Javier A. Adachi, John J. Mathewson, Margaret W. DuPont, Ernesto Palazzini, Lise M. Riopel, David Ashley & Francisco Martinez‐Sandoval. (2001) Rifaximin versus Ciprofloxacin for the Treatment of Traveler's Diarrhea: A Randomized, Double‐Blind Clinical Trial. Clinical Infectious Diseases 33:11, pages 1807-1815.
Crossref
Crossref
Janus P. Ong & Kevin D. Mullen. (2001) Hepatic encephalopathy. European Journal of Gastroenterology & Hepatology 13:4, pages 325-334.
Crossref
Crossref
Zhi-Dong Jiang, Shi Ke, Ernesto Palazzini, Lise Riopel & Herbert Dupont. (2000) In Vitro Activity and Fecal Concentration of Rifaximin after Oral Administration. Antimicrobial Agents and Chemotherapy 44:8, pages 2205-2206.
Crossref
Crossref
J. Fernández & A. Mas. (2000) Tratamiento de la encefalopatía hepática. Fármacos y mecanismos de acción. Medicine - Programa de Formación Médica Continuada Acreditado 8:10, pages 516-521.
Crossref
Crossref